Primary and metastatic breast carcinoma: Initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose

Richard L. Wahl, Robert L. Cody, Gary Hutchins, Elizabeth E. Mudgett

Research output: Contribution to journalArticle

410 Citations (Scopus)

Abstract

The authors assessed whether breast cancers can be detected by means of positron emission tomography (PET) with the positron-emitter-labeled glucose analogue 2-[fluorine-18]-fluoro-2-deoxy-D-glucose (FDG). In 12 patients with primary and/or metastatic breast cancer, PET images of F-18 distribution in vivo were obtained approximately 1 hour after intravenous injection of 10 mCi of FDG. Scan findings were correlated with other imaging data and physical examination and biopsy results. Ten of 10 primary breast cancers were imaged by means of FDG PET with a tumor:background FDG uptake ratio of 8.1 (median). Ten of 10 bone metastases were imaged with a tumor:normal bone uptake ratio of 6.05 (median). Five of five known soft-tissue metastases and four previously unsuspected nodal lesions were found with PET. No false-positive foci of FDG uptake were demonstrated. In two cases with negative mammograms due to dense breast parenchyma, FDG PET clearly delineated the primary tumors. These preliminary data demonstrate the feasibility and substantial potential of PET scanning with FDG to detect and localize both primary and metastatic breast cancers.

Original languageEnglish (US)
Pages (from-to)765-770
Number of pages6
JournalRadiology
Volume179
Issue number3
StatePublished - Jun 1991
Externally publishedYes

Fingerprint

Fluorine
Deoxyglucose
Positron-Emission Tomography
Breast Neoplasms
Glucose
Neoplasm Metastasis
Bone and Bones
Neoplasms
Intravenous Injections
Physical Examination
Breast
Electrons
Biopsy

Keywords

  • Breast neoplasms, diagnosis, 00.32, 00.33
  • Breast neoplasms, metastases, 00.33
  • Breast neoplasms, radionuclide studies, 00.121, 00.12987
  • Emission CT, 00.1299
  • Glucose
  • Radionuclide imaging, in diagnosis of neoplasms

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Primary and metastatic breast carcinoma : Initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. / Wahl, Richard L.; Cody, Robert L.; Hutchins, Gary; Mudgett, Elizabeth E.

In: Radiology, Vol. 179, No. 3, 06.1991, p. 765-770.

Research output: Contribution to journalArticle

@article{2890127b6f294188a9f8c6456da54d88,
title = "Primary and metastatic breast carcinoma: Initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose",
abstract = "The authors assessed whether breast cancers can be detected by means of positron emission tomography (PET) with the positron-emitter-labeled glucose analogue 2-[fluorine-18]-fluoro-2-deoxy-D-glucose (FDG). In 12 patients with primary and/or metastatic breast cancer, PET images of F-18 distribution in vivo were obtained approximately 1 hour after intravenous injection of 10 mCi of FDG. Scan findings were correlated with other imaging data and physical examination and biopsy results. Ten of 10 primary breast cancers were imaged by means of FDG PET with a tumor:background FDG uptake ratio of 8.1 (median). Ten of 10 bone metastases were imaged with a tumor:normal bone uptake ratio of 6.05 (median). Five of five known soft-tissue metastases and four previously unsuspected nodal lesions were found with PET. No false-positive foci of FDG uptake were demonstrated. In two cases with negative mammograms due to dense breast parenchyma, FDG PET clearly delineated the primary tumors. These preliminary data demonstrate the feasibility and substantial potential of PET scanning with FDG to detect and localize both primary and metastatic breast cancers.",
keywords = "Breast neoplasms, diagnosis, 00.32, 00.33, Breast neoplasms, metastases, 00.33, Breast neoplasms, radionuclide studies, 00.121, 00.12987, Emission CT, 00.1299, Glucose, Radionuclide imaging, in diagnosis of neoplasms",
author = "Wahl, {Richard L.} and Cody, {Robert L.} and Gary Hutchins and Mudgett, {Elizabeth E.}",
year = "1991",
month = "6",
language = "English (US)",
volume = "179",
pages = "765--770",
journal = "Radiology",
issn = "0033-8419",
publisher = "Radiological Society of North America Inc.",
number = "3",

}

TY - JOUR

T1 - Primary and metastatic breast carcinoma

T2 - Initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose

AU - Wahl, Richard L.

AU - Cody, Robert L.

AU - Hutchins, Gary

AU - Mudgett, Elizabeth E.

PY - 1991/6

Y1 - 1991/6

N2 - The authors assessed whether breast cancers can be detected by means of positron emission tomography (PET) with the positron-emitter-labeled glucose analogue 2-[fluorine-18]-fluoro-2-deoxy-D-glucose (FDG). In 12 patients with primary and/or metastatic breast cancer, PET images of F-18 distribution in vivo were obtained approximately 1 hour after intravenous injection of 10 mCi of FDG. Scan findings were correlated with other imaging data and physical examination and biopsy results. Ten of 10 primary breast cancers were imaged by means of FDG PET with a tumor:background FDG uptake ratio of 8.1 (median). Ten of 10 bone metastases were imaged with a tumor:normal bone uptake ratio of 6.05 (median). Five of five known soft-tissue metastases and four previously unsuspected nodal lesions were found with PET. No false-positive foci of FDG uptake were demonstrated. In two cases with negative mammograms due to dense breast parenchyma, FDG PET clearly delineated the primary tumors. These preliminary data demonstrate the feasibility and substantial potential of PET scanning with FDG to detect and localize both primary and metastatic breast cancers.

AB - The authors assessed whether breast cancers can be detected by means of positron emission tomography (PET) with the positron-emitter-labeled glucose analogue 2-[fluorine-18]-fluoro-2-deoxy-D-glucose (FDG). In 12 patients with primary and/or metastatic breast cancer, PET images of F-18 distribution in vivo were obtained approximately 1 hour after intravenous injection of 10 mCi of FDG. Scan findings were correlated with other imaging data and physical examination and biopsy results. Ten of 10 primary breast cancers were imaged by means of FDG PET with a tumor:background FDG uptake ratio of 8.1 (median). Ten of 10 bone metastases were imaged with a tumor:normal bone uptake ratio of 6.05 (median). Five of five known soft-tissue metastases and four previously unsuspected nodal lesions were found with PET. No false-positive foci of FDG uptake were demonstrated. In two cases with negative mammograms due to dense breast parenchyma, FDG PET clearly delineated the primary tumors. These preliminary data demonstrate the feasibility and substantial potential of PET scanning with FDG to detect and localize both primary and metastatic breast cancers.

KW - Breast neoplasms, diagnosis, 00.32, 00.33

KW - Breast neoplasms, metastases, 00.33

KW - Breast neoplasms, radionuclide studies, 00.121, 00.12987

KW - Emission CT, 00.1299

KW - Glucose

KW - Radionuclide imaging, in diagnosis of neoplasms

UR - http://www.scopus.com/inward/record.url?scp=0025911120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025911120&partnerID=8YFLogxK

M3 - Article

C2 - 2027989

AN - SCOPUS:0025911120

VL - 179

SP - 765

EP - 770

JO - Radiology

JF - Radiology

SN - 0033-8419

IS - 3

ER -